Desloratadine CAS 100643-71-8
Introduction：Basic information about Desloratadine CAS 100643-71-8, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Desloratadine Basic information
| Product Name: | Desloratadine |
| Synonyms: | AzoMyr;Neoclarityn;NSC 675447;Opulis;Desloratadine(Clarinex);5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro- 11-(4-piperidinylidene)-;Desloratadine for system suitability;Loratadine Related Compound A (15 mg) (8-chloro-6,11-dihydro-11(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b] pyridine) |
| CAS: | 100643-71-8 |
| MF: | C19H19ClN2 |
| MW: | 310.82 |
| EINECS: | 638-878-8 |
| Product Categories: | FLUVENT;Inhibitors;Other APIs;API;Active Pharmaceutical Ingredients;Antihistaminic;Various Metabolites and Impurities;Intermediates & Fine Chemicals;Metabolites;Pharmaceuticals;Heterocycles;Metabolites & Impurities;100643-71-8 |
| Mol File: | 100643-71-8.mol |
Desloratadine Chemical Properties
| Melting point | 150-151°C |
| Boiling point | 467.9±45.0 °C(Predicted) |
| density | 1?+-.0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: >10mg/mL |
| pka | 10.27±0.20(Predicted) |
| form | powder |
| color | White to Light orange to Yellow |
| Merck | 14,2922 |
| BCS Class | 1 |
| InChI | InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2 |
| InChIKey | JAUOIFJMECXRGI-UHFFFAOYSA-N |
| SMILES | C12/C(=C3\CCNCC\3)/C3=CC=C(Cl)C=C3CCC1=CC=CN=2 |
| CAS DataBase Reference | 100643-71-8(CAS DataBase Reference) |
Safety Information
| WGK Germany | 3 |
| RTECS | DE8011000 |
| HS Code | 2933399090 |
| Storage Class | 11 - Combustible Solids |
| Description | Desloratadine is a second generation of tricyclic antihistamine. It is a H1-receptor antagonist which has anti-inflammatory activity. Its affinity to the H1 receptor is higher than most other H1-receptor antagonists. Desloratadine works by blocking a certain natural substance (histamine) which is produced during an allergic reaction. Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system. Desloratadine is used to treat nasal and non-nasal symptoms (watery eyes, runny nose, itching eyes/nose, sneezing, and itching) of seasonal allergic rhinitis. It is also used to relieve chronic itching caused by hives. |
| Chemical Properties | Beige Solid |
| Originator | Sepracor (US) |
| Uses | Desloratadine has been used to test its effect on embryoid body development in in vitro gastrulation model of P19C5 stem cells. It has also been used as an antihistamine mimic in rats and to treat lung cancer (A549) and glioblastoma (U87) cells in various cellular studies. |
| Uses | Nonsedating-type histamine H1-receptor antagonist. An active metabolite of Loratadine. Also inhibits generation and release of inflammatory mediators from basophils and mast cells. |
| Uses | antiinflammatory |
| Uses | For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria. |
| Definition | ChEBI: Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis nd chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. |
| Indications | Desloratadine (Clarinex) is an active metabolite of loratadine. A 5 mgdaily dose has been shown to be effective. There is no evidence that it offersany advantage over loratadine.Fexofenadine (like its parent compound terfenadine) may rarely promotecardiac arrhythmias (24). No significant difference in efficacy has been notedin the nonsedating H1 blockers. Combinations of nonsedating antihistaminesin the morning and sedating antihistamines in the evening may be more costeffective than increasing doses of the nonsedating agent. |
| Manufacturing Process | To a solution of 10.9 g (0.1 mole) of ethylchloroformate in 300 ml ofanhydrous benzene is added dropwise, with stirring at room temperature, asolution of 16.2 g (0.05 M) of 11-(N-methyl-4-piperidylidene)-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridine in 200 ml of benzene.The solution is stirred and is heated under reflux overnight (16-20 hours). Themixture is cooled and is poured into ice water and the organic layer isseparated, washed with water, dried, and then concentrated to dryness. Theresidue is triturated with petroleum ether and a white solid of 8-chloro-6,11-dihydro-11-(1-ethoxycarbonyl-4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine having a melting point of 128-130°C isrecrystallized from isopropyl ether after decolorization with decolorizingcarbon. To 12 g of sodium hydroxide in 30 ml ethyl alcohol (70%) add 6 g of 8-chloro6,11-dihydro-11-(1-ethoxycarbonyl-4-piperidylidene)-5Hbenzo[5,6]cyclohepta[1,2-b]pyridine and reflux with stirring for 24 hours.After about the first 6-8 hours an additional 30 ml of 70% ethyl alcohol maybe added. Remove about 50% of the solvent by distillation in vacuo. Add asmall amount of ice water and acidify with glacial acetic acid. Extract withchloroform (6-8 times), since the product precipitates from the acetic acidsolution as a thick emulsion which cannot be filtered. Concentrate thechloroform extracts to a small volume and precipitate the product with hexaneto give crude 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5Hbenzo[5,6]cyclohepta[1,2-b]pyridine acetic acid salt, m.p. 197-200°C.Recrystallize from benzene-hexane to obtain the product, m.p. 199-200°C.Yield 4.0-4.5 g. |
| Brand name | Clarinex (Schering-Plough). |
| Therapeutic Function | Antiallergic |
| General Description | Desloratadine, 8-chloro-6,11-dihydro-11-(4-piperdinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine(Clarinex) is a white to off-white powder that is slightlysoluble in water, but very soluble in ethanol and propyleneglycol. It is the proposed active metabolite loratadine and hasa very similar receptor binding and safety profile. It is indicated for the symptomatic relief of pruritus andreduction in the number and size of hives in chronic idiopathicurticaria patients 6 months of age and older and for therelief of the nasal and nonnasal symptoms of perennial allergicrhinitis (in patients 6 months of age and older) and seasonalallergic rhinitis (in patients 2 years of age and older). Desloratadine is extensively metabolized to 3-hydroxydesloratadine,also an active metabolite, which is subsequentlyglucuronidated . The cytochrome enzymesresponsible for the formation of 3-hydroxydesloratadinehave not been reported. Coadministration ofdesloratadine with CYP3A4 inhibitors results in marginalincreases in plasma concentrations of desloratadine and3-hydroxydesloratadine, but no significant changes in safetyor efficacy. The mean elimination half-life of desloratadineis about 6 hours, and the drug and its metabolites areeliminated in the urine and feces. |
| Biochem/physiol Actions | Desloratadine is a selective and nonsedating histamine H1 receptor antagonist, an active metabolite of loratadine (Claritin), used to relieve hay fever and allergy symptoms with less drowsiness than other antihistamines; does not significantly inhibits cardiac K+ channels at clinically achievable blood levels. Free from antimuscarinic/anticholinergic effects. |
| Clinical Use | Desloratadine was launched as an improved version of Schering-Plough'sClaritin? (Loratadine), for the treatment of nasal and non-nasal symptoms of seasonalallergic rhinitis (SAR). Desloratadine can be prepared by a 7-step synthesis starting with aRitter reaction on 2-cyano-3-picoline and involving successively alkylation with 3-chlorobenzyl chloride, dehydration, Grignard reaction with the piperidine magnesiumchloride, intramolecular cyclization in strong acidic medium, and finally demethylation ofthe piperidine. Desloratadine (the descarboethoxyloratadine) is a biologically activemetabolite of the second-generation antihistamine Ioratadine. Desloratadine is a nonsedatingcompetitive histamine H1 receptor antagonist with increased potency andimproved safety as compared to Ioratadine. When compared with other H1 antagonists asan inhibitor of histamine-induced calcium flux in CHO cells, desloratadine was found to bemore potent than most H1 antagonists (such as the widely used terfenadine, fexofenadine,cetirizine, Ioratadine and astemizole) in this assay. Desloratadine is also a potentantagonist of muscarinic M1 and M3 receptors (not M2) indicating anticholinergic activity.These effects may be the explanation for the unexpected decongestant effects ofdesloratadine reported in clinical trials. Desloratadine appears to be devoid of significanteffects on potassium channels and does not appear to suffer from adverse interaction withcytochrome P450 inhibitors. Clinical studies have shown that it does not induce sedation orcardiac arrhythmias and does not potentiate the effects of alcohol. Apparent total body clearance is in the range of 114-201 l/h and the mean elimination half life is 19-34.6 h in human. Desloratadine is available as 5-mg tablets, which is the once-daily recommendeddose for adults and children above 12 years. It may be taken without regard to food. Thetreatment not only improved symptoms of SAR but also improved patient ratings of nasalcongestion. The FDA also has issued an "approvable" letter for this agent for the treatmentof chronic idiopathic urticaria (ClU). |
| References | [1] https://www.drugbank.ca [2] Raif S. Geha, Eli O. Meltzer (2001) Desloratadine: A new, nonsedating, oral antihistamine, The Journal of Allergy and Clinical Immunology,107, 751-762 |
Desloratadine Preparation Products And Raw materials
| Raw materials | N-Methyl Desloratadine-->Sodium hydroxide-->Ethyl chloroformate-->2H-Pyrano[3,2-b]pyridine,3,4-dihydro-4-methylene-(9CI)-->Loratadine ketone-->N-T-BUTYL-3-METHYL PYRIDINE-2-CARBOXAMIDE-->100643-73-0-->1-Methylpiperdin-4-ylmagnesium chloride, 0.50 M in THF-->Loratadine-->8-Chloro-6,11-dihydro-11-(1-methyl-4-piperidinyl)-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ol-->3-[2-(3-CHLORO-PHENYL)-ETHYL]-PYRIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE-->3-[2-(3-Chlorophenyl)ethyl]-2-pyridinecarbonitrile-->8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one |
| Preparation Products | Sch 37370 |
